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Abstract We have studied the interaction of coenzyme Q with
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its
metabolites, 1-methyl-4-phenyl-2,3-dihydropyridinium
(MPDP+) and 1-methyl-4-phenylpyridinium (MPP+), the real
neurotoxin to cause Parkinson’s disease. Incubation of MPTP or
MPDP+ with rat brain synaptosomes induced complete reduction
of endogenous ubiquinone-9 and ubiquinone-10 to corresponding
ubiquinols. The reduction occurred in a time- and MPTP/
MPDP+ concentration-dependent manner. The reduction of
ubiquinone induced by MPDP+ went much faster than that by
MPTP. MPTP did not reduce liposome-trapped ubiquinone-10,
but MPDP+ did. The real toxin MPP+ did not reduce ubiquinone
in either of the systems. The reduction by MPTP but not
MPDP+ was completely prevented by pargyline, a type B
monoamine oxidase (MAO-B) inhibitor, in the synaptosomes.
The results indicate that involvement of MAO-B is critical for
the reduction of ubiquinone by MPTP but that MPDP+ is a
reductant of ubiquinone per se. It is suggested that ubiquinone
could be an electron acceptor from MPDP+ and promote the
conversion from MPDP+ to MPP+ in vivo, thus accelerating the
neurotoxicity of MPTP.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in-
duces Parkinsonism in humans [1] and experimental animals
[2^5]. The mechanism of neurotoxicity of MPTP has been
investigated extensively in the 1980s. Studies have elucidated
that MPTP is metabolized by type B monoamine oxidase (EC
1.4.3.4, MAO-B) to the initial two-electron oxidation product,
1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP), which
undergoes further oxidation to the ultimate four-electron ox-
idation product, 1-methyl-4-phenylpyridinium (MPP) [6],
which is sequestered in dopaminergic neurons by the high-
a⁄nity dopamine uptake pump [7]. The toxicity of MPP
apparently occurs by selective inhibition of NADH-ubiqui-
none oxidoreductase (complex I) of the mitochondrial respi-
ratory chain, resulting in ATP depletion and ¢nally cell death
[8,9]. An alternative mechanism of MPTP toxicity may in-
volve the generation of toxic active oxygen species [10,11].
However, it is still unclear how MPDP is transformed to
MPP in vivo.
Ubiquinone, which is also known as coenzyme Q, is a lipid-
soluble compound composed of a redox active quinoid moiety
and a hydrophobic chain. Coenzyme Q, the electron acceptor
for complexes I and II, acts as an electron and proton carrier
in mitochondrial and bacterial electron transport linked to
ATP synthesis. In addition, ubiquinol, the reduced form of
ubiquinone, functions as a radical-scavenging antioxidant pre-
venting the chain initiation and/or propagation of lipid per-
oxidation in biological membranes and in low-density lipopro-
tein. Its high degree of hydrophobicity and its widespread
occurrence in biological membranes suggest an important
role of ubiquinol in cellular defense against oxidative damage
[12]. So, coenzyme Q plays an important role in the two areas
implicated in the neurotoxicity of MPTP, mitochondrial dys-
function and oxidative damage. Despite the extensive studies
on MPTP metabolism and neurotoxicity and the essential role
of coenzyme Q in the electron transport chain, the e¡ect of
coenzyme Q on MPTP metabolism has not been investigated.
We now show for the ¢rst time, to our knowledge, that MPTP
through its metabolite by MAO-B, MPDP, reduces ubiqui-
none to its reduced form. The results indicate that coenzyme
Q may play an important role in transformation of MPDP
to MPP in vivo.
2. Materials and methods
2.1. Materials
MPTP hydrochloride, pargyline (N-benzyl-N-methyl propargyl-
amine), and Chelex 100 were obtained from Sigma Chemical Co.
(St. Louis, MO, USA). MPDP perchlorate and MPP iodide were
purchased from Research Biochemicals International (Natick, MA,
USA). Phosphatidylcholine (14:0) and sodium borohydride were
from Wako Pure Chemical Co. (Osaka, Japan). Ubiquinone-9 and
ubiquinone-10 were kindly supplied by Eisai Co. (Tokyo, Japan).
Ubiquinol-9 and ubiquinol-10 were obtained by reduction of corre-
sponding quinones with sodium borohydride. All solvents used for
high performance liquid chromatography (HPLC) analysis were
from Nacalai Tesque, Inc. (Kyoto, Japan). All other chemicals used
were of analytical grade.
2.2. Experimental animals and isolation of synaptosomes
Male Wistar rats weighing 180^200 g were purchased from Clea Co.
(Tokyo, Japan) and acclimatized for 1 week before use. Synaptosomes
were prepared from the whole brain of rats by the discontinuous
density gradient centrifugation method of Dodd et al. [13].
2.3. Incubation of synaptosomes with MPTP, MPDP+ or MPP+
Synaptosomes (1 mg protein/ml) were incubated with MPTP
(MPDP or MPP) at various concentrations under air at 37‡C in
10 mM phosphate-bu¡ered saline (PBS, pH 7.4). PBS was pre-treated
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 1 4 4 4 - 1
*Corresponding author. Fax: (81) (3) 5452-5201.
E-mail: eniki@oxygen.rcast.u-tokyo.ac.jp
Abbreviations: EC, electrochemical; HPLC, high performance liquid
chromatography; MAO, monoamine oxidase; MPDP, 1-methyl-4-
phenyl-2,3-dihydropyridinium; MPP, 1-methyl-4-phenylpyridinium;
MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
FEBS 22878 11-11-99
FEBS 22878FEBS Letters 461 (1999) 196^200
with Chelex 100 to remove traces of metal ions. The suspension of
synaptosomes was pre-equilibrated for 5 min at 37‡C before the ad-
dition of other substances. In the experiment with the MAO-B inhib-
itor, pargyline was added to the suspensions at the same time as
MPTP.
2.4. Incubation of liposome-trapped coenzyme Q with MPTP, MPDP+
or MPP+
The liposome was prepared as follows. Phosphatidylcholine and
ubiquinone-10 were dissolved in chloroform and the solution was
placed in a £ask. The solvent was removed to obtain a thin ¢lm.
An appropriate amount of PBS was added and the ¢lm was slowly
peeled o¡ by shaking to obtain a white, milky liposome solution.
MPTP, MPP or MPDP was added to a portion of the liposome
solution in a reaction vessel, mixed and incubated under air at 37‡C.
Aliquots were taken out at indicated times and injected directly on an
HPLC system (see Section 2.5) to measure the content of ubiquinone
and ubiquinol.
2.5. Extraction and measurement of ubiquinone and ubiquinol
Synaptosomes (0.4 mg protein) were separated from the reaction
medium, resuspended in 0.2 ml water, and frozen and thawed twice
using liquid nitrogen. Lipophilic substances including coenzyme Q
were extracted by chloroform/methanol (2:1, v/v). The lower phase
was separated out and evaporated under a stream of nitrogen. The
residue was redissolved in methanol for HPLC analysis. The HPLC
system was the same as used previously [14].
2.6. Measurement of protein content
Protein content was determined by the BCA protein assay kit ac-
cording to the maker’s instruction (Pierce, Rockford, IL, USA).
3. Results and discussion
3.1. HPLC separation of coenzyme Q
As shown in Fig. 1, synaptosomal ubiquinones and ubi-
quinols were separated and quantitated by HPLC with UV
and electrochemical (EC) detectors. Two kinds of coenzyme
Q, ubiquinone-9 and ubiquinone-10, exist in rat brain synap-
tosomes. The content of ubiquinone-9 was twice that of ubi-
quinone-10. In control synaptosomes, the level of ubiquinols
was very low. After incubation of synaptosomes with MPTP,
the peaks of ubiquinones disappeared and the peaks of ubi-
quinols increased signi¢cantly.
3.2. Interaction of MPTP with coenzyme Q
The reduction of ubiquinone to ubiquinol by MPTP in the
synaptosomes occurred time-dependently (Fig. 2A). The rate
of reducing endogenous ubiquinone-9 (0.018 nmol/mg pro-
tein/min) was twice that of ubiquinone-10 (0.009 nmol/mg
protein/min). Almost all the endogenous ubiquinone-9 and
ubiquinone-10 was depleted in 30 min, as observed by the
concomitant production of ubiquinol-9 and ubiquinol-10, re-
spectively. The levels of ubiquinols were very stable after-
wards during the 2-h incubation. Fig. 2B shows that the re-
duction of synaptosomal ubiquinones proceeded MPTP
concentration-dependently. There were two phases of MPTP
concentration-dependent reduction of ubiquinones, and at the
concentration of 1 mM, the reduction reached a plateau.
When exogenous ubiquinone-10 (20 times higher than the
level of endogenous ubiquinone-10) was added to synapto-
somes, it could also be reduced quantitatively (data not
shown).
Fig. 1. HPLC analysis of ubiquinones and ubiquinols in extracts
from rat brain synaptosomes with UV and EC detectors. A: Con-
trol synaptosomes. B: Synaptosomes incubated with MPTP (1 mM)
for 30 min at 37‡C. Peaks 1, 2, 3, and 4 stand for ubiquinol-9,
ubiquinol-10, ubiquinone-9, and ubiquinone-10, respectively.
Fig. 2. Reduction of endogenous ubiquinones to their reduced forms
by MPTP in rat brain synaptosomes. A: Time-dependent study. Rat
brain synaptosomes (1 mg protein/ml) were incubated in PBS (10
mM, pH 7.4) in the presence of 0.5 mM MPTP at 37‡C under air
for 120 min. Aliquots were removed at various time intervals and
levels of ubiquinols and ubiquinones were measured by HPLC. B:
Concentration-dependent study. Rat brain synaptosomes (1 mg pro-
tein/ml) were incubated with MPTP at various concentrations in
PBS (10 mM, pH 7.4) at 37‡C under air for 30 min. R, ubiqui-
none-9; O, ubiquinol-9; b, ubiquinone-10; a, ubiquinol-10. Data
are means þ S.D. of three independent determinations.
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To determine whether MPTP reduces ubiquinone by itself
or through its metabolites, the following experiments were
carried out. First, the e¡ect of pargyline, a MAO-B inhibitor,
on the reduction of synaptosomal ubiquinone by MPTP was
studied. MAO-B has a crucial role in MPTP-induced degen-
eration of the nigrostriatal dopaminergic neuronal pathway.
Chiba et al. discovered that rodent brain preparations could
metabolize MPTP to MPP in vitro [6] and that potent in-
hibitors of MAO-B could inhibit the MPP formation from
MPTP, suggesting MAO-B is responsible for the oxidative
metabolism of MPTP. In vivo studies showed that inhibitors
of MAO-B, but not MAO-A, could protect monkeys and mice
from the neurotoxicity of MPTP, indicating that its in situ
oxidation by MAO-B accounts for the cytotoxicity in the
brain [15,16]. As shown in Fig. 3, after 3 h of treatment
with MPTP, synaptosomal ubiquinone-9 and ubiquinone-10
exist in their reduced forms. Strikingly, no reduction of ubi-
quinones was observed in synaptosomes treated with pargy-
line and MPTP together. In agreement with the cytotoxicity
study, MAO-B plays a crucial role in the reduction. Second,
MPTP was incubated with liposome-trapped ubiquinone-10.
It can be seen from Fig. 4 that MPTP did not react or reduce
liposome-trapped ubiquinone-10. In addition, it was con-
¢rmed that MPP, the real neurotoxin and the ¢nal metabo-
lite of MPTP, did not possess the property to reduce ubi-
quinone in either rat brain synaptosomes or liposomes (data
not shown).
3.3. Interaction of MPDP+ with coenzyme Q
We further investigated the interaction between coenzyme
Q and MPDP. In rat brain synaptosomes, MPDP reduced
ubiquinone-9 and ubiquinone-10 to their reduced forms time-
dependently and the reduction was much faster than that by
MPTP (Fig. 5A). MPDP led to complete reduction of ubi-
quinones to their reduced forms in 5 min. The reduction also
occurred MPDP concentration-dependently (Fig. 5B).
MPDP at concentrations greater than 0.05 mM reduced all
the synaptosomal ubiquinone. Not only did MPDP reduce
synaptosomal ubiquinone, but it also reduced liposome-
trapped ubiquinone (Fig. 6), which indicates that MPDP
directly reduced ubiquinone. The reduction of liposomal ubi-
quinone was MPDP concentration- and time-dependent.
These results indicate that MPTP reduces synaptosomal ubi-
quinone through its metabolism by MAO-B to MPDP. In
addition, MPTP and MPDP also reduced ubiquinones in rat
liver mitochondria (unpublished data) in a similar way as in
the synaptosomes.
MPDP is chemically reactive and has a tendency to under-
go disproportionation at high concentrations and at alkaline
Fig. 3. E¡ect of pargyline on the reduction of ubiquinones by
MPTP in rat brain synaptosomes. Rat brain synaptosomes (1 mg
protein/ml) were incubated with MPTP (1 mM) in the presence or
absence of pargyline (1 WM) in PBS (10 mM, pH 7.4) at 37‡C under
air for 3 h. Aliquots were taken and levels of ubiquinols and ubi-
quinones were measured by HPLC. UQ-9, ubiquinone-9; UQH2-9,
ubiquinol-9; UQ-10, ubiquinone-10; UQH2-10, ubiquinol-10. Data
are means þ S.D. of three independent determinations.
Fig. 4. E¡ect of MPTP on liposome-trapped ubiquinone. Liposomes
of 14:0 phosphatidylcholine (2.83 mM) containing ubiquinone-10
(4.0 WM) were incubated with MPTP (2 mM) in PBS (10 mM, pH
7.4) at 37‡C under air. Aliquots were removed at various time inter-
vals and levels of ubiquinone-10 (b) and ubiquinol-10 (a) were
measured by HPLC.
Fig. 5. Interaction of synaptosomal ubiquinones with MPDP. A:
Time-dependent study. Rat brain synaptosomes (1 mg protein/ml)
were incubated in PBS (10 mM, pH 7.4) in the presence of 0.1 mM
MPDP at 37‡C under air. Aliquots were taken at various time in-
tervals and levels of ubiquinols and ubiquinones were measured by
HPLC. B: Concentration-dependent study. Rat brain synaptosomes
(1 mg protein/ml) were incubated with MPDP at various concen-
trations in PBS (10 mM, pH 7.4) at 37‡C under air for 5 min. R,
ubiquinone-9; O, ubiquinol-9; b, ubiquinone-10; a, ubiquinol-10.
Data are means þ S.D. of three independent determinations.
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pH values. But this does not appear to be a physiologically
signi¢cant source of MPP, because at neutral pH the dispro-
portionation hardly proceeds. In fact, at the early stage of the
study on the neurotoxicity of MPTP it was found that the
decrease of MPDP was accelerated in the presence of rat
brain mitochondria [17]. Because both heat-denatured mito-
chondria and addition of the MAO-B inhibitor pargyline did
not show any e¡ect on the observed rate of decomposition of
MPDP to MPP, it was concluded that the conversion was
not enzyme-mediated [17,18], and the reason why brain mito-
chondrial preparations enhanced decomposition of MPDP is
still unknown, although it was later argued that the decom-
position of MPDP to MPP may be catalyzed by metal
chelates [19] and neuromelanin [20]. Our observation should
shed new light on the metabolism of MPTP in vivo. The
results enable us to propose the metabolism of MPTP as
shown in Scheme 1. MPTP is oxidized by MAO-B to
MPDP, which can transfer its two electrons to the oxidized
form of coenzyme Q present ubiquitously in biological mem-
branes, and thus enhance the production of MPP. Coenzyme
Q could be a critical factor in the mechanism of toxicity of
MPTP in this respect. This may raise the question whether it
is proper or not to use coenzyme Q to ameliorate the toxicity
of MPTP because recently coenzyme Q-10 has been proposed
to improve a MPTP-induced Parkinsonism model [21,22].
It has been suggested that a free radical-mediated mecha-
nism could be involved in MPTP toxicity (see reviews [10,11]).
MPTP produces hydrogen peroxide by the action of MAO-B.
MPTP, MPDP and MPP themselves catalyze superoxide
radical production under certain conditions. However, it has
been reported that both MPTP and MPDP inhibited lipid
peroxidation in isolated hepatocytes [23], liver homogenates
[24] and brain homogenates [24]. The reason has been myste-
rious. Our ¢nding that MPTP and MPDP are capable of
reducing ubiquinone to ubiquinol can fully explain the pre-
vious observation. It is obvious that the interaction between
MPDP and ubiquinone will signi¢cantly increase the total
antioxidant potency because ubiquinol serves as a potent anti-
oxidant in biological membranes. We also observed that in the
presence of MPTP or MPDP, but not MPP, the depletion
of K-tocopherol and production of phospholipid hydroperox-
ides in synaptosomes were completely inhibited during oxida-
tion induced by peroxyl radical and the e¡ect is ascribed to
the antioxidant activity of ubiquinol constantly reduced from
ubiquinone by MPTP and MPDP (Shi and Niki, unpub-
lished data).
Attempts to prevent the toxic consequences of MPTP ex-
posure in vivo via the use of antioxidants have been carried
out. Substances with antioxidant activity such as cytosine [25],
Ginkgo biloba [26] and melatonin [27,28] have been used to
prevent neurotoxicity of MPTP in animal models. In this re-
spect, it seems the improved antioxidant capacity by the in-
teraction of MPDP with coenzyme Q would decrease the
toxicity of MPTP. This leads coenzyme Q to play a contra-
dictory role in the toxicity of MPTP. Coenzyme Q accelerates
the toxicity of MPTP by enhancing the transformation of
MPDP to MPP, while it may ameliorate the toxicity of
MPTP by acting as an e⁄cient antioxidant.
In conclusion, this is the ¢rst observation that ubiquinone
can be reduced to its reduced form by MPTP and its metab-
olite MPDP. This provides a new route of the metabolism of
MPTP in vivo. MPTP is metabolized to MPDP by MAO-B
and MPDP is transformed to MPP by reducing ubiqui-
none. In this respect, coenzyme Q may play a critical role in
the toxicity of MPTP.
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